| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220212 | Gynecologic Oncology | 2018 | 6 Pages |
Abstract
Dose-modified patients were at a higher risk of disease progression and death. The need for chemotherapy dose modification may identify patients at greater risk for adverse outcomes in advanced stage EOC and PPC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Alexander B. Olawaiye, James J. Java, Thomas C. Krivak, Michael Friedlander, David G. Mutch, Gretchen Glaser, Melissa Geller, David M. O'Malley, Robert M. Wenham, Roger B. Lee, Diane C. Bodurka, Thomas J. Herzog, Michael A. Bookman,